Angelica Fasolo

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Vivek Subbiah, Ulrik Lassen, Élena Elez et al. · The Lancet Oncology · 2020 · 489 citations

Surgical Oncology, Oncology, Gastrointestinal Oncology +9

PD-1 Blockade in Anaplastic Thyroid Carcinoma

Jaume Capdevila, Lori J. Wirth, Thomas Ernst et al. · Journal of Clinical Oncology · 2020 · 335 citations · Full text

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

Fabrice André, Sara A. Hurvitz, Angelica Fasolo et al. · Journal of Clinical Oncology · 2016 · 165 citations

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

Guy Jérusalem, Angelica Fasolo, Véronique Dièras et al. · Breast Cancer Research and Treatment · 2010 · 139 citations

Breast Oncology, Medicine, Pharmacology +6

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

Gianluca Del Conte, Cristiana Sessa, Roger von Moos et al. · British Journal of Cancer · 2014 · 102 citations · Full text